alexa Abstract | Randomized, Optimal Dose Finding, Phase Ii Study of Tri-Weekly NabPaclitaxel in Patients with Metastatic Breast Cancer (ABROAD)
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Protocol Open Access

Abstract

hNab-paclitaxel (nab-PTX) is a paclitaxel albumin-stabilized nanoparticle formulation. Nab-PTX has demonstrated superiority over conventional PTX in terms of objective response rate (ORR) and progression free survival in metastatic breast cancer. However chemotherapy induced grade 3 or higher peripheral neuropathy (CIPN) was more frequently observed in nab-PTX. More recent phase 3 study CALGB 40502 could not prove superiority of weekly nab-PTX to weekly PTX because of higher incidence of toxicity by standard dose of nab-PTX. Taken together, there is a room for the further study to find the optimal dose of nab-PTX. In a single arm phase 2 study CA002-0LD, low dose tri-weekly nab-PTX 175 mg/m2 showed good ORR (39.5%) and no CIPN of grade 3 or higher. Thus we conducted randomized phase 2 study (ABROAD) for optimal dose finding of nab-PTX, comparing three different dose of tri-weekly nab-PTX (180 mg/m2 vs. 220 mg/m2 vs. 260 mg/m2 ) in patients with metastatic breast cancer.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Fumikata Hara, Tsutomu Takashima, Junji Tsurutani, Tsuyoshi Saito, Naruto Taira, Kosuke Kashiwabara, Tomohiko Aihara, Hirofumi Muka

Keywords

Metastatic breast cancer, Chemotherapy, Nab-paclitaxel, Optimal dose, Peripheral neuropathy, HRQoL, Single-nucleotide polymorphisms, Clinical Trials Japan

Share This Page

Additional Info

Loading
Loading Please wait..
 
 
 
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords